Cargando…

Effect of 24 weeks of intensification with a CCR5-antagonist on the decay of the HIV-1 latent reservoir

Detalles Bibliográficos
Autores principales:	Díaz, L, Gutiérrez, C, Page, C, Lorente, R, Hernández-Novoa, B, Vallejo, A, Domínguez, E, Abad, M, Madrid, N, Moreno, A, Pérez-Elías, MJ, Rubio, R, Muñoz-Fernández, MA, Moreno, S
Formato:	Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999383/ http://dx.doi.org/10.1186/1758-2652-13-S3-O13

Ejemplares similares

Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected
por: Gutiérrez, Carolina, et al.
Publicado: (2011)

Clearing the HIV reservoir by transplanting CCR5 deficient stem cells
por: Hütter, Gero
Publicado: (2011)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists
por: Brumme, CJ, et al.
Publicado: (2010)

Homeostatic proliferation of memory T cells and expansion of the HIV-1 latent reservoir
por: Bosque, A, et al.
Publicado: (2010)

Co-receptor usage prediction at quasispecies level using ultra-deep pyrosequencing on both circulating and proviral hiv in patients candidates to CCR5 antagonist treatment
por: Abbate, Isabella, et al.
Publicado: (2010)

Humanized anti CCR4 antibody KW0761 targets HTLV-1 infected CD4+ CCR4+ and CD8+CCR4+ T cells to treat HAM/TSP
por: Yamano, Yoshihisa, et al.
Publicado: (2015)

The reservoir of latent HIV
por: Chen, Jing, et al.
Publicado: (2022)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
por: López-Huertas, María Rosa, et al.
Publicado: (2017)

SOLTI (Solid Tumor Intensification) Group experience with high-dose chemotherapy treatment for early breast carcinoma
por: Funes, H Cortés, et al.
Publicado: (2005)

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010)

HCMV Antivirals and Strategies to Target the Latent Reservoir
por: Perera, Marianne R., et al.
Publicado: (2021)

52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B
por: Piratvisuth, Teerha, et al.
Publicado: (2013)

Purging the HIV-1 reservoir through the disruption of the PD-1 pathway
por: DaFonseca, S, et al.
Publicado: (2010)

The diversity of latent TB
por: Young, Douglas
Publicado: (2010)

CCR9 Antagonists in the Treatment of Ulcerative Colitis
por: Bekker, Pirow, et al.
Publicado: (2015)

Heterogeneity of HIV-1 latent reservoirs
por: Zhao, Jia-Cong, et al.
Publicado: (2020)

Separating latent and acute TB
por: Doherty, T Mark
Publicado: (2010)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
por: López-Huertas, María Rosa, et al.
Publicado: (2020)

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model
por: Ochoa-Callejero, Laura, et al.
Publicado: (2013)

Oral abstracts of the HIV Cure and Reservoir Symposium 2017
Publicado: (2017)

CCR6 mediates the intracellular HIV inhibitory activity of human beta-defensin 2
por: Sun, Lingling, et al.
Publicado: (2006)

The global distribution of CCR5 delta 32 polymorphism: role in HIV-1 protection
por: Gupta, Anuroopa, et al.
Publicado: (2012)

Approaches to eradication of latent HIV infection
por: Margolis, David
Publicado: (2013)

Modulation of inflammatory pain in response to a CCR2/CCR5 antagonist in rodent model
por: Okamoto, Masayuki, et al.
Publicado: (2013)

Chemokine receptor CCR5 mediates resistance to West Nile Virus infection in mouse and man
por: Murphy, Philip
Publicado: (2006)

Monoclonal antibodies and small-molecules as distinct subclasses of CCR5-targeted therapies for HIV-1
por: Olson, William C
Publicado: (2006)

Human and chicken antibodies to CCR5-ECL1 block mucosal and systemic HIV infection
por: Lopalco, Lucia, et al.
Publicado: (2006)

What is the future of CCR5 antagonists in rheumatoid arthritis?
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

How to Define the Latent Reservoir: Tools of the Trade
por: Barton, Kirston M., et al.
Publicado: (2016)

HIV-1 latent reservoir: size matters
por: Hodel, Flavia, et al.
Publicado: (2016)

Search for small molecule activators of latent HIV
por: Geleziunas, Romas, et al.
Publicado: (2012)

Development of a CCR5-tropic HIV-1 fusion inhibition assay amenable to high-throughput screening for topical microbicides
por: Beer, B, et al.
Publicado: (2006)

The forces driving clonal expansion of the HIV-1 latent reservoir
por: Liu, Runxia, et al.
Publicado: (2020)

Chemokines in rheumatoid arthritis: novel, potential therapeutic targets of the CCR2 chemokine receptor signaling pathway
por: Matsushima, K, et al.
Publicado: (2003)

Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1
por: Sanz, Marta, et al.
Publicado: (2023)

Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1
por: Sanz, Marta, et al.
Publicado: (2023)

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

Attacking latent HIV: towards eradication of HIV infection
por: Margolis, DM
Publicado: (2006)

New transcription regulatory mechanisms of latent HIV LTR
por: Rafati, Haleh, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_s9onfgs1ir1h8imv6sdb5bpmmp